Active Ingredient History
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Coronary Syndrome (Phase 4)
Acute Kidney Injury (Phase 4)
Analgesics, Opioid (Phase 4)
Anemia, Sickle Cell (Phase 2/Phase 3)
Anesthesia (Phase 4)
Arthritis, Juvenile (Phase 4)
Arthritis, Rheumatoid (Phase 3)
Aspirin (Phase 4)
Back Pain (Phase 3)
Biological Availability (Phase 1)
Brain Edema (Phase 2)
Breast Neoplasms (Phase 2/Phase 3)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Chronic Pain (Phase 3)
Colorectal Neoplasms (Phase 1)
Coronary Disease (Phase 4)
COVID-19 (Phase 4)
Drug Interactions (Phase 1)
Dyskinesias (Phase 2)
Dyspepsia (Phase 4)
Eosinophilic Esophagitis (Phase 2)
Esophageal Motility Disorders (Phase 4)
Esophagitis (Phase 3)
Gastric Emptying (Phase 4)
Healthy Volunteers (Phase 1)
Heartburn (Phase 4)
Heart Failure (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hemorrhage (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 4)
Immune System Diseases (Phase 2/Phase 3)
Immunoglobulin G4-Related Disease (Phase 2)
Intestinal Neoplasms (Phase 3)
Laryngomalacia (Phase 1/Phase 2)
Lupus Erythematosus, Systemic (Phase 1)
Lymphoma (Phase 3)
Melanoma (Phase 1)
Multiple Myeloma (Phase 2)
Myocardial Infarction (Phase 4)
Neoplasms (Phase 1)
Osteoarthritis (Phase 3)
Peptic Ulcer ()
Pneumonia, Aspiration (Phase 4)
Psoriasis (Phase 1)
Pulmonary Arterial Hypertension (Phase 2)
Respiratory Aspiration (Phase 4)
Schizophrenia (Phase 4)
Spinal Diseases (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Diseases (Phase 1)
Stomach Neoplasms (Phase 2)
Stomach Ulcer (Phase 4)
Stroke (Phase 2)
Thyroid Cancer, Papillary (Phase 1)
Ulcer (Phase 4)
Volunteers (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue